CLL
From the Journals
Phase 3 data: Zanubrutinib bests standard CLL treatment
Results could spur FDA approval as frontline therapy.
Conference Coverage
Many die waiting for `last-chance’ therapy
Blood cancer patients, especially those with myeloma, face hospice and death while awaiting CAR T-cell therapy.
Feature
Life and death decisions: What keeps oncologists up at night
“It’s part of the discomfort you live with as a patient and oncologist, and when I leave the clinic, that’s one thing that follows me home.”
Feature
CAR T-cell therapy turns 10 and finally earns the word ‘cure’
“We have a couple dozen patients who are 5, 6, 7, 9 years out or more without further therapy. That feels like a cure to me.”
From the Journals
Heed cardiac risk of BTKis for CLL
New consensus statement warns about cardiac risk of using BTKis, but a cardio-oncologist specialist questions its conclusions.
Feature
Drug shortages plague hematology, but preparedness helps
The plight of desperate patients is getting attention – and some remedies.
News from the FDA/CDC
FDA warns of increased risk of death with CLL, lymphoma drug
“The trial also found Copiktra was associated with a higher risk of serious side effects ...”
News
FDA warning: Lymphoma drug heightens risk of death
FDA alert warns of increased risk of death and serious side affects with duvelisib, approved in 2018 to treat adults with CLL or SLL whose two...
Conference Coverage
‘Superior’ CLL regimen cuts chemo in half
Where chemo is still used to treat CLL, this three-cycle regimen combined with ibrutinib and obinutuzumab shows progression-free and overall...
News
FDA approves liso-cel as second-line therapy for LBCL
Liso-cel could now become a “new standard of care for patients after failure of first-line therapy,” offering significantly improved outcomes for...
Conference Coverage
Venetoclax combos prolong progression-free CLL survival
Time-limited targeted therapy with venetoclax plus obinutuzumab outperforms chemoimmunotherapy for CLL progression-free survival.